Can use of popular weight loss medications reduce behaviors linked to violent crime?

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for diabetes and obesity, but studies have found evidence that the medications may also influence behavior, such as supporting impulse control and reducing substance use and alcohol consumption by potentially interacting with the brain’s reward and stress systems. New research in Criminology adds to this growing evidence.

When investigators analyzed data from a 2025 nationally representative US survey involving 821 adults who had ever used GLP-1 medications, they found that while impulsivity and alcohol use were strongly associated with committing violent crime, these associations were significantly weaker among current GLP-1 RA users compared with former users. So even when a GLP-1 RA user drinks or acts impulsively, the situation is less likely to escalate into engaging in violent criminality. More thorough analyses showed that this finding was especially consistent related to impulsivity, but less so with alcohol use.

The findings suggest that GLP-1 RAs may lessen the extent to which certain established risk factors translate into violent behavior.

“As GLP-1 medications become increasingly widespread, understanding their broader behavioral effects becomes an important public health and criminological question that requires careful study,” said corresponding author Daniel C. Semenza, PhD, of Rutgers University.

URL upon publication: https://onlinelibrary.wiley.com/doi/10.1111/1745-9125.70058

Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.

About the Journal
Criminology is devoted to the study of crime and deviant behavior. Interdisciplinary in scope, the journal publishes articles that advance the theoretical and research agenda of criminology and criminal justice.

About Wiley      
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.